Literature DB >> 11884293

Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation.

Xiaobo Lin1, Gustav Schonfeld, Pin Yue, Zhouji Chen.   

Abstract

Humans and genetically engineered mice with hypobetalipoproteinemia due to truncation-producing mutations of the apolipoprotein B (apoB) gene frequently have fatty livers, because the apoB defect impairs the capacity of livers to export triglycerides (TGs). We assessed the adaptation of hepatic lipid metabolism in our apoB-38.9-bearing mice. Hepatic TG contents were 2- and 4-fold higher in heterozygous and homozygous mice, respectively, compared with wild-type mice. Respective in vivo hepatic fatty acid synthetic rates were reduced to 40% and 15% of the wild-type rate. Hepatic mRNAs for sterol regulatory element-binding protein (SREBP)-1c, fatty acid synthase (FAS), and stearoyl coenzyme A desaturase-1 were coordinately decreased. FAS and SREBP-1c mRNA levels were strongly and positively correlated with each other and inversely correlated with hepatic TGs, suggesting that impaired TG export is a potent inhibitor of fatty acid synthesis. In contrast, levels of plasma beta-hydroxybutyrate and of hepatic carnitine palmitoyl transferase and peroxisome proliferator-activated receptor-alpha mRNAs were not altered, implying that beta-oxidation was not affected. Fasting followed by refeeding increased hepatic fatty acid synthesis 56-fold over fasting in normal and heterozygous mice but only 24-fold in homozygous mice. Parallel changes occurred in FAS and SREBP-1c mRNAs. Thus, impairment of very low density lipoprotein export downregulates hepatic fatty acid synthesis, but the adaptation is incomplete, resulting in fatty livers. The signals mediating suppression of FAS and SREBP-1c levels remain to be identified.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884293     DOI: 10.1161/hq0302.105271

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  18 in total

1.  Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.

Authors:  Zhouji Chen; Patrick A Vigueira; Kari T Chambers; Angela M Hall; Mayurranjan S Mitra; Nathan Qi; William G McDonald; Jerry R Colca; Rolf F Kletzien; Brian N Finck
Journal:  J Biol Chem       Date:  2012-05-23       Impact factor: 5.157

Review 2.  Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.

Authors:  Tiffany Thomas; Henry Ginsberg
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

3.  Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity.

Authors:  Christoph Zechner; Ling Lai; Juliet F Zechner; Tuoyu Geng; Zhen Yan; John W Rumsey; Deanna Collia; Zhouji Chen; David F Wozniak; Teresa C Leone; Daniel P Kelly
Journal:  Cell Metab       Date:  2010-12-01       Impact factor: 27.287

Review 4.  Genetic determinants of hepatic steatosis in man.

Authors:  Amanda J Hooper; Leon A Adams; John R Burnett
Journal:  J Lipid Res       Date:  2011-01-18       Impact factor: 5.922

5.  Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis.

Authors:  Yan Wang; Fabiana Quagliarini; Viktoria Gusarova; Jesper Gromada; David M Valenzuela; Jonathan C Cohen; Helen H Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

6.  PGC-1β and ChREBP partner to cooperatively regulate hepatic lipogenesis in a glucose concentration-dependent manner.

Authors:  Kari T Chambers; Zhouji Chen; Ling Lai; Teresa C Leone; Howard C Towle; Anastasia Kralli; Peter A Crawford; Brian N Finck
Journal:  Mol Metab       Date:  2013-05-09       Impact factor: 7.422

7.  Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Authors:  Richard G Lee; Wuxia Fu; Mark J Graham; Adam E Mullick; Donna Sipe; Danielle Gattis; Thomas A Bell; Sheri Booten; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2012-12-06       Impact factor: 5.922

8.  Fatty liver and insulin resistance: not always linked.

Authors:  Gustav Schonfeld; Pin Yue; Xiaobo Lin; Zhouji Chen
Journal:  Trans Am Clin Climatol Assoc       Date:  2008

9.  Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice.

Authors:  Nisreen Soufi; Angela M Hall; Zhouji Chen; Jun Yoshino; Sara L Collier; James C Mathews; Elizabeth M Brunt; Carolyn J Albert; Mark J Graham; David A Ford; Brian N Finck
Journal:  J Biol Chem       Date:  2014-09-11       Impact factor: 5.157

10.  A nutrigenomic framework to identify time-resolving responses of hepatic genes in diet-induced obese mice.

Authors:  Hyoung-Sam Heo; Eunjung Kim; Seon-Min Jeon; Eun-Young Kwon; Su-Kyung Shin; Hyojung Paik; Cheol-Goo Hur; Myung-Sook Choi
Journal:  Mol Cells       Date:  2013-06-26       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.